SCHEMBL1639211

SCHEMBL1639211

O=C(C/C(=N/NC(=O)c1sc2ccccc2c1Cl)C(F)(F)F)c1ccco1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.57
ALDH1A1 P00352 8/20 0.57
HPGD P15428 6/20 0.57
KMT2A Q03164 7/20 0.54
MEN1 O00255 6/20 0.54
RAB9A P51151 6/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
TP53 P04637 1/20 0.53
KDM4E B2RXH2 4/20 0.50
LMNA P02545 2/20 0.50
OGG1 O15527 2/20 0.48
GAA P10253 3/20 0.47
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
SLC12A2 P55011 1/20 0.44
SLC12A5 Q9H2X9 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
POLB P06746 1/20 0.44
AGTR1 P30556 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639215 1.00 MAPT (0.57) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL12726693 1.00 MAPT (0.57) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL1637345 0.89 HPGD (0.57) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL1637344 0.89 HPGD (0.57) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL12726733 0.89 HPGD (0.57) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL13971520 0.88 MAPT (0.51) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL1639137 0.82 MAPT (0.59) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL1639136 0.82 MAPT (0.59) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL1638767 0.76 HPGD (0.58) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL1638768 0.76 HPGD (0.58) MAPTALDH1A1HPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 MAPT 85/4885ALDH1A1 592/4885HPGD 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.